PMID- 22277178
OWN - NLM
STAT- MEDLINE
DCOM- 20120515
LR  - 20181201
IS  - 1751-7133 (Electronic)
IS  - 1527-5299 (Linking)
VI  - 18
IP  - 1
DP  - 2012 Jan-Feb
TI  - Levosimendan produces an additional clinical and hemodynamic benefit in patients 
      with decompensated heart failure successfully submitted to a fluid removal 
      treatment.
PG  - 47-53
LID - 10.1111/j.1751-7133.2011.00261.x [doi]
AB  - A pivotal role in treating decompensated heart failure (HF) is played by 
      inotropes and calcium sensitizers such as levosimendan. In this study, the 
      authors evaluated whether levosimendan could determine further clinical and 
      hemodynamic benefits in 31 HF patients (New York Heart Association [NYHA] class 
      III or IV), after successful treatment with diuretics (n=15) or ultrafiltration 
      (n=16). Systolic, diastolic, dicrotic, and mean arterial pressures; systemic 
      vascular resistance (SVR); some classic hemodynamic variables (cardiac output 
      [CO], stroke volume [SV], dP/dt(max) ); and indices of cardiovascular system 
      performance (cardiac cycle efficiency [CCE], cardiac power output) have been 
      assessed by the pressure recording analytical method (PRAM), a minimally invasive 
      monitoring system, before levosimendan infusion, at the end of treatment (EoT), 
      and 36 hours after EoT (post-36). A significant increase in CCE, CO, SV, and 
      dP/dt(max) and a significant decrease in diastolic and dicrotic arterial 
      pressures and in SVR have been observed at EoT and at post-36. After the addition 
      of levosimendan, a further reduction in signs and symptoms of HF and NYHA class 
      was observed. Five patients showed an opposite trend of several hemodynamic 
      parameters without any significant clinical improvement (nonresponders). In 
      conclusion, most HF patients treated with diuretics or ultrafiltration receive 
      additional clinical and hemodynamic benefits from levosimendan. The 
      characterization of nonresponders could help in optimizing its use.
CI  - (c) 2011 Wiley Periodicals, Inc.
FAU - Giglioli, Cristina
AU  - Giglioli C
AD  - Medical and Surgical Cardiac Step Down Unit, Department of Heart and Vessels, 
      Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 
      cristinagiglioli@yahoo.it
FAU - Cecchi, Emanuele
AU  - Cecchi E
FAU - Landi, Daniele
AU  - Landi D
FAU - Chiostri, Marco
AU  - Chiostri M
FAU - Spini, Valentina
AU  - Spini V
FAU - Valente, Serafina
AU  - Valente S
FAU - Gensini, Gian F
AU  - Gensini GF
FAU - Romano, Salvatore M
AU  - Romano SM
LA  - eng
PT  - Journal Article
DEP - 20111112
PL  - United States
TA  - Congest Heart Fail
JT  - Congestive heart failure (Greenwich, Conn.)
JID - 9714174
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hydrazones)
RN  - 0 (Pyridazines)
RN  - 349552KRHK (Simendan)
SB  - IM
MH  - Aged
MH  - Blood Pressure
MH  - *Body Fluids
MH  - Cardiac Output
MH  - Cardiotonic Agents/*administration & dosage
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Hemodynamics
MH  - Humans
MH  - Hydrazones/*administration & dosage
MH  - Male
MH  - Monitoring, Physiologic
MH  - Prospective Studies
MH  - Pyridazines/*administration & dosage
MH  - Simendan
MH  - Treatment Outcome
EDAT- 2012/01/27 06:00
MHDA- 2012/05/16 06:00
CRDT- 2012/01/27 06:00
PHST- 2012/01/27 06:00 [entrez]
PHST- 2012/01/27 06:00 [pubmed]
PHST- 2012/05/16 06:00 [medline]
AID - 10.1111/j.1751-7133.2011.00261.x [doi]
PST - ppublish
SO  - Congest Heart Fail. 2012 Jan-Feb;18(1):47-53. doi: 
      10.1111/j.1751-7133.2011.00261.x. Epub 2011 Nov 12.